| 13/12/24 | 08:43:54 | 13 Dec 2024 | | HER2 presentation at SABCS |
| 15/11/24 | 07:00:06 | 15 Nov 2024 | | Research on HER2 assay kit showcased at AACR |
| 15/11/24 | 07:00:06 | 15 Nov 2024 | | Parsortix based PD-L1 assay showcased at AACR |
| 13/11/24 | 07:00:10 | 13 Nov 2024 | | ANGLE presents two posters at EACR |
| 11/11/24 | 07:00:10 | 11 Nov 2024 | | Parsortix enriched CTC & ctDNA in NSCLC patients |
| 17/10/24 | 07:00:09 | 17 Oct 2024 | | Publication demonstrates CTC profiling potential |
| 26/09/24 | 07:01:01 | 26 Sept 2024 | | 100th publication supporting Parsortix system use |
| 26/09/24 | 07:00:13 | 26 Sept 2024 | | Half-year Report |
| 23/09/24 | 07:00:07 | 23 Sept 2024 | | Exclusive agreement for DNA NGS panel |
| 19/09/24 | 07:00:11 | 19 Sept 2024 | | Agreement with Recursion Pharmaceuticals |
| 17/09/24 | 07:00:11 | 17 Sept 2024 | | Notice of Interim Results and Webcast |
| 22/08/24 | 07:00:15 | 22 Aug 2024 | | Data supporting FDA approval published in Journal |
| 01/08/24 | 07:00:20 | 1 Aug 2024 | | Independent Parsortix study |
| 18/07/24 | 10:08:22 | 18 Jul 2024 | | Standard form for notification of major holdings |
| 12/07/24 | 15:38:33 | 12 Jul 2024 | | Standard form for notification of major holdings |
| 11/07/24 | 15:07:44 | 11 Jul 2024 | | Result of 2024 Annual General Meeting |
| 21/06/24 | 07:00:12 | 21 Jun 2024 | | Result of open offer |
| 18/06/24 | 14:41:25 | 18 Jun 2024 | | Posting of 2023 Annual Report & Notice of the AGM |
| 11/06/24 | 07:00:10 | 11 Jun 2024 | | Parsortix and assays being showcased at EACR 2024 |
| 06/06/24 | 16:37:51 | 6 Jun 2024 | | Publication of Circular |
| 05/06/24 | 16:04:55 | 5 Jun 2024 | | Results of placing and subscription |
| 05/06/24 | 07:00:11 | 5 Jun 2024 | | Proposed Placing, Subscription and Open Offer |
| 05/06/24 | 07:00:10 | 5 Jun 2024 | | Preliminary Results |
| 16/05/24 | 07:00:13 | 16 May 2024 | | Study of ovarian cancer CTCs using Parsortix |
| 03/05/24 | 07:00:09 | 3 May 2024 | | New commercial agreement with large pharma |
| 24/04/24 | 07:00:10 | 24 Apr 2024 | | New commercial agreement with AstraZeneca |
| 22/04/24 | 07:00:10 | 22 Apr 2024 | | US and EU patents for innovative CellKeep™ slide |
| 08/04/24 | 07:00:09 | 8 Apr 2024 | | Parsortix HER2 assay showcased at AACR 2024 |
| 22/03/24 | 07:00:11 | 22 Mar 2024 | | Parsortix at European breast cancer conference |
| 22/01/24 | 07:00:11 | 22 Jan 2024 | | Potential utility in precision oncology |
| 10/01/24 | 12:57:47 | 10 Jan 2024 | | Standard form for notification of major holdings |
| 04/01/24 | 07:00:03 | 4 Jan 2024 | | Breakthrough clinical results |
| 02/01/24 | 07:00:05 | 2 Jan 2024 | | Contract announcement with Eisai Inc. |
| 11/12/23 | 07:00:15 | 11 Dec 2023 | | Broker Announcement |
| 11/12/23 | 07:00:11 | 11 Dec 2023 | | Parsortix unlocks opportunities for drug discovery |
| 05/12/23 | 07:00:14 | 5 Dec 2023 | | ANGLE launches Portrait+ CTC kit at SABCS |
| 09/11/23 | 07:00:19 | 9 Nov 2023 | | Launch of PD-L1 test to support cancer studies |
| 09/11/23 | 07:00:10 | 9 Nov 2023 | | Trading and business update |
| 25/10/23 | 07:00:14 | 25 Oct 2023 | | Supporting characterisation of CTCs in HNSCC |
| 03/10/23 | 07:00:09 | 3 Oct 2023 | | Parsortix outperforms standard for DTC harvest |
| 29/09/23 | 07:00:16 | 29 Sept 2023 | | Parsortix system showcased at ACTC conference |
| 07/09/23 | 07:00:04 | 7 Sept 2023 | | Interim Results for the period ended 30 June 2023 |
| 04/09/23 | 07:00:05 | 4 Sept 2023 | | ANGLE launch of Portrait Flex assay |
| 15/08/23 | 07:00:06 | 15 Aug 2023 | | ANGLE notice of interim results |
| 28/06/23 | 16:54:33 | 28 Jun 2023 | | Result of 2023 Annual General Meeting |
| 27/06/23 | 12:24:09 | 27 Jun 2023 | | Standard form for notification of major holdings |
| 05/06/23 | 07:00:09 | 5 Jun 2023 | | ANGLE announces senior management appointments |
| 25/05/23 | 07:00:08 | 25 May 2023 | | Pharma services contract with Artios Pharma |
| 22/05/23 | 07:00:05 | 22 May 2023 | | Board change - appointment of new Chairman |
| 21/04/23 | 12:04:09 | 21 Apr 2023 | | ANGLE presentation via Investor Meet Company |
